<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39334845</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1078</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14091078</ELocationID><Abstract><AbstractText>Systematic inflammatory response syndrome (SIRS) and the accompanying sepsis pose a huge threat to human health worldwide. Heparin is a part of the standard supportive care for the disease. However, the molecular mechanism is not fully understood yet, and the potential signaling pathways that play key roles have not yet been elucidated. In this paper, the main findings regarding the molecular mechanisms associated with the beneficial effects of heparin, including inhibiting HMGB-1-driven inflammation reactions, histone-induced toxicity, thrombo-inflammatory response control and the new emerging mechanisms are concluded. To set up the link between the preclinical research and the clinical effects, the outcomes of the clinical trials are summarized. Then, the structure and function relationship of heparin is discussed. By providing an updated analysis of the above results, the paper highlights the feasibility of heparin as a possible alternative for sepsis prophylaxis and therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medi-X Pingshan, Southern University of Science and Technology, Shenzhen 518118, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yaojia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bingyan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xinran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Lige</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen 518057, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lirong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen 518057, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Xuewen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen 518057, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yishu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21978114</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006496">Heparinoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006496" MajorTopicYN="N">Heparinoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anti-inflammation</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">structure and function relationship</Keyword></KeywordList><CoiStatement>Authors Lige Ren, Lirong Deng and Xuewen Jin were employed by the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334845</ArticleId><ArticleId IdType="pmc">PMC11430252</ArticleId><ArticleId IdType="doi">10.3390/biom14091078</ArticleId><ArticleId IdType="pii">biom14091078</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003;348:138–150. doi: 10.1056/NEJMra021333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra021333</ArticleId><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaukonen K.M., Bailey M., Pilcher D., Cooper D.J., Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 2015;372:1629–1638. doi: 10.1056/NEJMoa1415236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1415236</ArticleId><ArticleId IdType="pubmed">25776936</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Poll T., Shankar-Hari M., Wiersinga W.J. The immunology of sepsis. Immunity. 2021;54:2450–2464. doi: 10.1016/j.immuni.2021.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.10.012</ArticleId><ArticleId IdType="pubmed">34758337</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.-L. Current sepsis therapeutics. EBioMedicine. 2022;86:104318. doi: 10.1016/j.ebiom.2022.104318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104318</ArticleId><ArticleId IdType="pmc">PMC9782815</ArticleId><ArticleId IdType="pubmed">36470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C.M., French C., Machado F.R., Mcintyre L., Ostermann M., Prescott H.C. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit. Care Med. 2021;49:e1063–e1143. doi: 10.1097/CCM.0000000000005337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005337</ArticleId><ArticleId IdType="pubmed">34605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M., Wang G., Xie J. Immune dysregulation in sepsis: Experiences, lessons and perspectives. Cell Death Discov. 2023;9:465. doi: 10.1038/s41420-023-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-023-01766-7</ArticleId><ArticleId IdType="pmc">PMC10730904</ArticleId><ArticleId IdType="pubmed">38114466</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell J.A. Management of sepsis. New Engl. J. Med. 2006;355:1699–1713. doi: 10.1056/NEJMra043632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra043632</ArticleId><ArticleId IdType="pubmed">17050894</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Aschenbrenner A.C., Bauer M., Bock C., Calandra T., Gat-Viks I., Kyriazopoulou E., Lupse M., Monneret G., Pickkers P., et al. The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nat. Immunol. 2024;25:19–28. doi: 10.1038/s41590-023-01660-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01660-5</ArticleId><ArticleId IdType="pubmed">38168953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonsdale D.O., Shah R.V., Lipman J. Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. Front. Med. 2020;7:588863. doi: 10.3389/fmed.2020.588863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.588863</ArticleId><ArticleId IdType="pmc">PMC7738462</ArticleId><ArticleId IdType="pubmed">33344475</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K., Venkatesh B., Finfer S. Sepsis and septic shock: Current approaches to management. Intern. Med. J. 2019;49:160–170. doi: 10.1111/imj.14199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14199</ArticleId><ArticleId IdType="pubmed">30754087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R.S., Moldawer L.L., Opal S.M., Reinhart K., Turnbull I.R., Vincent J.L. Sepsis and septic shock. Nat. Rev. Dis. Primers. 2016;2:16045. doi: 10.1038/nrdp.2016.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.45</ArticleId><ArticleId IdType="pmc">PMC5538252</ArticleId><ArticleId IdType="pubmed">28117397</ArticleId></ArticleIdList></Reference><Reference><Citation>Papafilippou L., Claxton A., Dark P., Kostarelos K., Hadjidemetriou M. Nanotools for Sepsis Diagnosis and Treatment. Adv. Healthc. Mater. 2021;10:e2001378. doi: 10.1002/adhm.202001378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202001378</ArticleId><ArticleId IdType="pubmed">33236524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones C.J., Beni S., Limtiaco J.F., Langeslay D.J., Larive C.K. Heparin characterization: Challenges and solutions. Annu. Rev. Anal. Chem. 2011;4:439–465. doi: 10.1146/annurev-anchem-061010-113911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-anchem-061010-113911</ArticleId><ArticleId IdType="pubmed">21469955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever R., Page C.P. Novel drug development opportunities for heparin. Nat. Rev. Drug Discov. 2002;1:140–148. doi: 10.1038/nrd724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd724</ArticleId><ArticleId IdType="pubmed">12120095</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu S., Yu S., Wang L., Ma X., Li X. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: A systematic review and meta-analysis. BMC Anesthesiol. 2022;22:28. doi: 10.1186/s12871-021-01545-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-021-01545-w</ArticleId><ArticleId IdType="pmc">PMC8777179</ArticleId><ArticleId IdType="pubmed">35062871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Chi C., Guo L., Wang X., Guo L., Sun J., Sun B., Liu S., Chang X., Li E. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: A systematic review and meta-analysis. Crit. Care. 2014;18:563. doi: 10.1186/s13054-014-0563-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-014-0563-4</ArticleId><ArticleId IdType="pmc">PMC4213495</ArticleId><ArticleId IdType="pubmed">25318353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Huang J.J., Luan Y.Y., Yang Z.J., Zhou Z.P., Zhang J.J., Yao Y.M., Wu M. Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: A retrospective analysis from the MIMIC-IV database. Burns Trauma. 2022;10:tkac029. doi: 10.1093/burnst/tkac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/burnst/tkac029</ArticleId><ArticleId IdType="pmc">PMC9501718</ArticleId><ArticleId IdType="pubmed">36168402</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Castelnuovo A., Costanzo S., Antinori A., Berselli N., Blandi L., Bonaccio M., Cauda R., Guaraldi G., Menicanti L., Mennuni M., et al. Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thromb. Haemost. 2021;121:1054–1065. doi: 10.1055/a-1347-6070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1347-6070</ArticleId><ArticleId IdType="pubmed">33412596</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaimes F., De La Rosa G., Morales C., Fortich F., Arango C., Aguirre D., Muñoz A. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) Crit. Care Med. 2009;37:1185–1196. doi: 10.1097/CCM.0b013e31819c06bc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819c06bc</ArticleId><ArticleId IdType="pubmed">19242322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienast J., Juers M., Wiedermann C.J., Hoffmann J.N., Ostermann H., Strauss R., Keinecke H.O., Warren B.L., Opal S.M. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost. 2006;4:90–97. doi: 10.1111/j.1538-7836.2005.01697.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01697.x</ArticleId><ArticleId IdType="pubmed">16409457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler P.R., Goligher E.C., Berger J.S., Neal M.D., McVerry B.J., Nicolau J.C., Gong M.N., Carrier M., Rosenson R.S., Reynolds H.R., et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:790–802. doi: 10.1056/NEJMoa2105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher E.C., Bradbury C.A., McVerry B.J., Lawler P.R., Berger J.S., Gong M.N., Carrier M., Reynolds H.R., Kumar A., Turgeon A.F., et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:777–789. doi: 10.1056/NEJMoa2103417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang L., Zhu H., Wang K., Liu Y., Yu F., Zhao W. Not Just Anticoagulation-New and Old Applications of Heparin. Molecules. 2022;27:6968. doi: 10.3390/molecules27206968.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27206968</ArticleId><ArticleId IdType="pmc">PMC9609994</ArticleId><ArticleId IdType="pubmed">36296562</ArticleId></ArticleIdList></Reference><Reference><Citation>Litov L., Petkov P., Rangelov M., Ilieva N., Lilkova E., Todorova N., Krachmarova E., Malinova K., Gospodinov A., Hristova R., et al. Molecular Mechanism of the Anti-Inflammatory Action of Heparin. Int. J. Mol. Sci. 2021;22:730. doi: 10.3390/ijms221910730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910730</ArticleId><ArticleId IdType="pmc">PMC8509397</ArticleId><ArticleId IdType="pubmed">34639073</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D. Heparin beyond anti-coagulation. Curr. Res. Transl. Med. 2021;69:103300. doi: 10.1016/j.retram.2021.103300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.retram.2021.103300</ArticleId><ArticleId IdType="pmc">PMC8257468</ArticleId><ArticleId IdType="pubmed">34237474</ArticleId></ArticleIdList></Reference><Reference><Citation>Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002;41:391–412. doi: 10.1002/1521-3773(20020201)41:3&lt;390::AID-ANIE390&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-3773(20020201)41:3&lt;390::AID-ANIE390&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">12491369</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold K., Liao Y.E., Liu J. Potential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage. Biomedicines. 2020;8:503. doi: 10.3390/biomedicines8110503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8110503</ArticleId><ArticleId IdType="pmc">PMC7697061</ArticleId><ArticleId IdType="pubmed">33207634</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Q., Zhang C., Wu X., Chen Y. Identification of a heparosan heptasaccharide as an effective anti-inflammatory agent by partial desulfation of low molecular weight heparin. Carbohydr. Polym. 2020;227:115312. doi: 10.1016/j.carbpol.2019.115312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2019.115312</ArticleId><ArticleId IdType="pubmed">31590876</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Esko J.D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 2014;83:129–157. doi: 10.1146/annurev-biochem-060713-035314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060713-035314</ArticleId><ArticleId IdType="pmc">PMC7851832</ArticleId><ArticleId IdType="pubmed">24606135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz U., Akhtar F., Xue J., Wan X., Zhang T., He S. Review: Inhibitory potential of low molecular weight Heparin in cell adhesion; emphasis on tumor metastasis. Eur. J. Pharmacol. 2021;892:173778. doi: 10.1016/j.ejphar.2020.173778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173778</ArticleId><ArticleId IdType="pubmed">33271153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Kang R., Tang D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 2022;54:91–102. doi: 10.1038/s12276-022-00736-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00736-w</ArticleId><ArticleId IdType="pmc">PMC8894452</ArticleId><ArticleId IdType="pubmed">35217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D., Kang R., Zeh H.J., Lotze M.T. The multifunctional protein HMGB1: 50 years of discovery. Nat. Rev. Immunol. 2023;23:824–841. doi: 10.1038/s41577-023-00894-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00894-6</ArticleId><ArticleId IdType="pubmed">37322174</ArticleId></ArticleIdList></Reference><Reference><Citation>Idoudi S., Bedhiafi T., Pedersen S., Elahtem M., Alremawi I., Akhtar S., Dermime S., Merhi M., Uddin S. Role of HMGB1 and its associated signaling pathways in human malignancies. Cell Signal. 2023;112:110904. doi: 10.1016/j.cellsig.2023.110904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2023.110904</ArticleId><ArticleId IdType="pubmed">37757902</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin K.L., Fischer B.M., Kummarapurugu A.B., Zheng S., Kennedy T.P., Rao N.V., Foster W.M., Voynow J.A. 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation. Am. J. Respir. Cell Mol. Biol. 2014;50:684–689. doi: 10.1165/rcmb.2013-0338RC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2013-0338RC</ArticleId><ArticleId IdType="pmc">PMC4068925</ArticleId><ArticleId IdType="pubmed">24325600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S., Kummarapurugu A.B., Afosah D.K., Sankaranarayanan N.V., Boothello R.S., Desai U.R., Kennedy T., Voynow J.A. 2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity. Am. J. Respir. Cell Mol. Biol. 2017;56:90–98. doi: 10.1165/rcmb.2016-0069OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2016-0069OC</ArticleId><ArticleId IdType="pmc">PMC5248960</ArticleId><ArticleId IdType="pubmed">27585400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Gauthier A.G., Kennedy T.P., Wang H., Velagapudi U.K., Talele T.T., Lin M., Wu J., Daley L., Yang X., et al. 2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function. Mol. Med. 2021;27:79. doi: 10.1186/s10020-021-00334-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-021-00334-y</ArticleId><ArticleId IdType="pmc">PMC8283750</ArticleId><ArticleId IdType="pubmed">34271850</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Ling Y., Huang M., Yin T., Gou S.M., Zhan N.Y., Xiong J.X., Wu H.S., Yang Z.Y., Wang C.Y. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine. 2015;72:36–42. doi: 10.1016/j.cyto.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2014.12.010</ArticleId><ArticleId IdType="pubmed">25562836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Wang X., Li Z., He Z., Yang X., Cheng X., Peng Y., Xue Q., Bai Y., Zhang R., et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021;54:454–467.e456. doi: 10.1016/j.immuni.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.007</ArticleId><ArticleId IdType="pubmed">33561388</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold K., Xu Y., Sparkenbaugh E.M., Li M., Han X., Zhang X., Xia K., Piegore M., Zhang F., Zhang X., et al. Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. Sci. Transl. Med. 2020;12:eaav8075. doi: 10.1126/scitranslmed.aav8075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav8075</ArticleId><ArticleId IdType="pmc">PMC7315409</ArticleId><ArticleId IdType="pubmed">32188725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Kang R., Fan X.G., Tang D. Release and activity of histone in diseases. Cell Death Dis. 2014;5:e1370. doi: 10.1038/cddis.2014.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.337</ArticleId><ArticleId IdType="pmc">PMC4454312</ArticleId><ArticleId IdType="pubmed">25118930</ArticleId></ArticleIdList></Reference><Reference><Citation>Szatmary P., Huang W., Criddle D., Tepikin A., Sutton R. Biology, role and therapeutic potential of circulating histones in acute inflammatory disorders. J. Cell Mol. Med. 2018;22:4617–4629. doi: 10.1111/jcmm.13797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13797</ArticleId><ArticleId IdType="pmc">PMC6156248</ArticleId><ArticleId IdType="pubmed">30085397</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ye Y., Peng K., Zeng Z., Chen L., Zeng Y. Histones: The critical players in innate immunity. Front. Immunol. 2022;13:1030610. doi: 10.3389/fimmu.2022.1030610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1030610</ArticleId><ArticleId IdType="pmc">PMC9720293</ArticleId><ArticleId IdType="pubmed">36479112</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsman G., Zeerleder S., Luken B.M. Extracellular histones, cell-free DNA, or nucleosomes: Differences in immunostimulation. Cell Death Dis. 2016;7:e2518. doi: 10.1038/cddis.2016.410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.410</ArticleId><ArticleId IdType="pmc">PMC5261016</ArticleId><ArticleId IdType="pubmed">27929534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildhagen K.C., García de Frutos P., Reutelingsperger C.P., Schrijver R., Aresté C., Ortega-Gómez A., Deckers N.M., Hemker H.C., Soehnlein O., Nicolaes G.A. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123:1098–1101. doi: 10.1182/blood-2013-07-514984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-07-514984</ArticleId><ArticleId IdType="pubmed">24264231</ArticleId></ArticleIdList></Reference><Reference><Citation>Reutelingsperger C.P.M., Gijbels M.J., Spronk H., Van Oerle R., Schrijver R., Ekhart P., de Kimpe S., Nicolaes G.A.F. M6229 Protects against Extracellular-Histone-Induced Liver Injury, Kidney Dysfunction, and Mortality in a Rat Model of Acute Hyperinflammation. Int. J. Mol. Sci. 2024;25:1376. doi: 10.3390/ijms25031376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25031376</ArticleId><ArticleId IdType="pmc">PMC10855969</ArticleId><ArticleId IdType="pubmed">38338654</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano F., Mizuno T., Mizumoto S., Yoshioka K., Takahashi K., Tsuboi N., Maruyama S., Yamada S., Nagamatsu T. Chondroitin sulfate protects vascular endothelial cells from toxicities of extracellular histones. Eur. J. Pharmacol. 2018;826:48–55. doi: 10.1016/j.ejphar.2018.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.02.043</ArticleId><ArticleId IdType="pubmed">29501579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N., Haggstrom L., Sohrabipour S., Dwivedi D.J., Liaw P.C. Investigations of the effectiveness of heparin variants as inhibitors of histones. J. Thromb. Haemost. 2022;20:1485–1495. doi: 10.1111/jth.15706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15706</ArticleId><ArticleId IdType="pubmed">35313081</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H. Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J. Thromb. Haemost. 2018;16:231–241. doi: 10.1111/jth.13911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13911</ArticleId><ArticleId IdType="pubmed">29193703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S.P., Darbousset R., Schoenwaelder S.M. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906–918. doi: 10.1182/blood-2018-11-882993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-882993</ArticleId><ArticleId IdType="pubmed">30642917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Yu H., Wang L., Zhou D., Duan X., Zhang X., Yin J., Luan S., Shi H. Heparin-network-mediated long-lasting coatings on intravascular catheters for adaptive antithrombosis and antibacterial infection. Nat. Commun. 2024;15:107. doi: 10.1038/s41467-023-44478-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44478-3</ArticleId><ArticleId IdType="pmc">PMC10761715</ArticleId><ArticleId IdType="pubmed">38167880</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J., Ding R., Zhao D., Zhang Z., Ma X. Unfractionated heparin attenuates lung vascular leak in a mouse model of sepsis: Role of RhoA/Rho kinase pathway. Thromb. Res. 2013;132:e42–e47. doi: 10.1016/j.thromres.2013.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2013.03.010</ArticleId><ArticleId IdType="pubmed">23566535</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Mu S., Li X., Liang Y., Wang L., Ma X. Unfractionated Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions. J. Surg. Res. 2019;238:175–185. doi: 10.1016/j.jss.2019.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2019.01.020</ArticleId><ArticleId IdType="pubmed">30771687</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Han S., Liu X., Wang T., Xu H., Xia B., Kong G., Li J., Zhu W., Hu H., et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. Exp. Ther. Med. 2020;19:913–922. doi: 10.3892/etm.2019.8285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.8285</ArticleId><ArticleId IdType="pmc">PMC6966138</ArticleId><ArticleId IdType="pubmed">32010252</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhu J., Liu K., Hu Y., Huang K., Pan S. Heparin ameliorates cerebral edema and improves outcomes following status epilepticus by protecting endothelial glycocalyx in mice. Exp. Neurol. 2020;330:113320. doi: 10.1016/j.expneurol.2020.113320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113320</ArticleId><ArticleId IdType="pubmed">32305420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Chen M., Zheng J., Li X., Zhang X. The Role of Heparin and Glycocalyx in Blood-Brain Barrier Dysfunction. Front. Immunol. 2021;12:754141. doi: 10.3389/fimmu.2021.754141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.754141</ArticleId><ArticleId IdType="pmc">PMC8724024</ArticleId><ArticleId IdType="pubmed">34992593</ArticleId></ArticleIdList></Reference><Reference><Citation>Masola V., Greco N., Gambaro G., Franchi M., Onisto M. Heparanase as active player in endothelial glycocalyx remodeling. Matrix Biol. Plus. 2022;13:100097. doi: 10.1016/j.mbplus.2021.100097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbplus.2021.100097</ArticleId><ArticleId IdType="pmc">PMC8749438</ArticleId><ArticleId IdType="pubmed">35036899</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Maier C.L., Helms J., Ferrer R., Thachil J., Levy J.H. Managing sepsis and septic shock in an endothelial glycocalyx-friendly way: From the viewpoint of surviving sepsis campaign guidelines. Ann. Intensive Care. 2024;14:64. doi: 10.1186/s13613-024-01301-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-024-01301-6</ArticleId><ArticleId IdType="pmc">PMC11043313</ArticleId><ArticleId IdType="pubmed">38658435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Bai J. Protective effects of heparin on endothelial cells in sepsis. Int. J. Clin. Exp. Med. 2015;8:5547–5552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484034</ArticleId><ArticleId IdType="pubmed">26131136</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zheng Z., Li X., Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine. 2012;60:114–121. doi: 10.1016/j.cyto.2012.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.06.008</ArticleId><ArticleId IdType="pubmed">22763042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauth A., Bręborowicz A., Ruan Y., Tang Q., Zadeh J.K., Böhm E.W., Pfeiffer N., Khedkar P.H., Patzak A., Vujacic-Mirski K., et al. Sulodexide Prevents Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress in Porcine Retinal Arterioles. Antioxidants. 2023;12:388. doi: 10.3390/antiox12020388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12020388</ArticleId><ArticleId IdType="pmc">PMC9952154</ArticleId><ArticleId IdType="pubmed">36829947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying J., Zhang C., Wang Y., Liu T., Yu Z., Wang K., Chen W., Zhou Y., Lu G. Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis. Front. Immunol. 2023;14:1172892. doi: 10.3389/fimmu.2023.1172892.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1172892</ArticleId><ArticleId IdType="pmc">PMC10444196</ArticleId><ArticleId IdType="pubmed">37614234</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D., Chen R., Zhang L., Rao Z., Ruan Y., Li L., Chu M., Zhang Y. Sulodexide attenuates endoplasmic reticulum stress induced by myocardial ischaemia/reperfusion by activating the PI3K/Akt pathway. J. Cell. Mol. Med. 2019;23:5063–5075. doi: 10.1111/jcmm.14367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14367</ArticleId><ArticleId IdType="pmc">PMC6653332</ArticleId><ArticleId IdType="pubmed">31120192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Wang K., Liu Q., Liu M., Zhang G., Feng K., Wang K., Ding X., Zhu H., Yang S., et al. A Novel Drug Candidate for Sepsis Targeting Heparanase by Inhibiting Cytokine Storm. Adv. Sci. 2024;11:e2403337. doi: 10.1002/advs.202403337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202403337</ArticleId><ArticleId IdType="pmc">PMC11304236</ArticleId><ArticleId IdType="pubmed">38810101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu S., Liu Y., Jiang J., Ding R., Li X., Li X., Ma X. Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury. Respir. Res. 2018;19:220. doi: 10.1186/s12931-018-0925-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-018-0925-6</ArticleId><ArticleId IdType="pmc">PMC6238311</ArticleId><ArticleId IdType="pubmed">30442128</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshun-Wilson L., Zhang R., Portran D., Nachury M.V., Toso D.B., Löhr T., Vendruscolo M., Bonomi M., Fraser J.S., Nogales E. Effects of α-tubulin acetylation on microtubule structure and stability. Proc. Natl. Acad. Sci. USA. 2019;116:10366–10371. doi: 10.1073/pnas.1900441116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1900441116</ArticleId><ArticleId IdType="pmc">PMC6535015</ArticleId><ArticleId IdType="pubmed">31072936</ArticleId></ArticleIdList></Reference><Reference><Citation>Meara C.H.O., Coupland L.A., Kordbacheh F., Quah B.J.C., Chang C.W., Simon Davis D.A., Bezos A., Browne A.M., Freeman C., Hammill D.J., et al. Neutralizing the pathological effects of extracellular histones with small polyanions. Nat. Commun. 2020;11:6408. doi: 10.1038/s41467-020-20231-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20231-y</ArticleId><ArticleId IdType="pmc">PMC7744542</ArticleId><ArticleId IdType="pubmed">33328478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ma X. The role of heparin in sepsis: Much more than just an anticoagulant. Br. J. Haematol. 2017;179:389–398. doi: 10.1111/bjh.14885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14885</ArticleId><ArticleId IdType="pubmed">28832958</ArticleId></ArticleIdList></Reference><Reference><Citation>Colicchia M., Perrella G., Gant P., Rayes J. Novel mechanisms of thrombo-inflammation during infection: Spotlight on neutrophil extracellular trap-mediated platelet activation. Res. Pract. Thromb. Haemost. 2023;7:100116. doi: 10.1016/j.rpth.2023.100116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2023.100116</ArticleId><ArticleId IdType="pmc">PMC10099327</ArticleId><ArticleId IdType="pubmed">37063765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y., Ling Y., Deng Q., Qiu Y., Shen J., Lai H., Chen Z., Huang C., Liang L., Li X., et al. HMGB1-Mediated Neutrophil Extracellular Trap Formation Exacerbates Intestinal Ischemia/Reperfusion-Induced Acute Lung Injury. J. Immunol. 2022;208:968–978. doi: 10.4049/jimmunol.2100593.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100593</ArticleId><ArticleId IdType="pubmed">35063996</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi A.A., Rovere-Querini P., D’Angelo A., Maugeri N. Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacol. Res. 2017;123:146–156. doi: 10.1016/j.phrs.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.08.008</ArticleId><ArticleId IdType="pubmed">28161237</ArticleId></ArticleIdList></Reference><Reference><Citation>An S., Raju I., Surenkhuu B., Kwon J.E., Gulati S., Karaman M., Pradeep A., Sinha S., Mun C., Jain S. Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. Ocul. Surf. 2019;17:589–614. doi: 10.1016/j.jtos.2019.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtos.2019.03.010</ArticleId><ArticleId IdType="pmc">PMC6721977</ArticleId><ArticleId IdType="pubmed">30965123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y.E., Xu Y., Arnold K., Zhang F., Li J., Sellers R., Yin C., Pagadala V., Inman A.M., Linhardt R.J., et al. Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis. Proc. Natl. Acad. Sci. USA. 2023;120:e2209528120. doi: 10.1073/pnas.2209528120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2209528120</ArticleId><ArticleId IdType="pmc">PMC9942825</ArticleId><ArticleId IdType="pubmed">36649428</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncato R., Angelini J., Pani A., Talotta R. Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2022;1867:159140. doi: 10.1016/j.bbalip.2022.159140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2022.159140</ArticleId><ArticleId IdType="pmc">PMC8894694</ArticleId><ArticleId IdType="pubmed">35248801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Liu Z., Dong Z., Pan J., Ma X. Azurocidin-induced inhibition of oxygen metabolism in mitochondria is antagonized by heparin. Exp. Ther. Med. 2014;8:1473–1478. doi: 10.3892/etm.2014.1939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1939</ArticleId><ArticleId IdType="pmc">PMC4186485</ArticleId><ArticleId IdType="pubmed">25289044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Wang Y., Zeng W., Mei X., Du S., Yan Y., Hao J., Zhang Z., Lu Y., Zhang C., et al. A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions. Carbohydr. Polym. 2020;249:116824. doi: 10.1016/j.carbpol.2020.116824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2020.116824</ArticleId><ArticleId IdType="pubmed">32933671</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 2020;18:1559–1561. doi: 10.1111/jth.14849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14849</ArticleId><ArticleId IdType="pmc">PMC9770920</ArticleId><ArticleId IdType="pubmed">32302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023;44:695–709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelliher S., Weiss L., Cullivan S., O’Rourke E., Murphy C.A., Toolan S., Lennon Á., Szklanna P.B., Comer S.P., Macleod H., et al. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. J. Thromb. Haemost. 2022;20:1008–1014. doi: 10.1111/jth.15660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15660</ArticleId><ArticleId IdType="pmc">PMC9305123</ArticleId><ArticleId IdType="pubmed">35102689</ArticleId></ArticleIdList></Reference><Reference><Citation>Potje S.R., Costa T.J., Fraga-Silva T.F.C., Martins R.B., Benatti M.N., Almado C.E.L., de Sá K.S.G., Bonato V.L.D., Arruda E., Louzada-Junior P., et al. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients. Life Sci. 2021;276:119376. doi: 10.1016/j.lfs.2021.119376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119376</ArticleId><ArticleId IdType="pmc">PMC7997864</ArticleId><ArticleId IdType="pubmed">33781826</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N., et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183:1043–1057. doi: 10.1016/j.cell.2020.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra R.S., Kandimalla R. Engaging the spikes: Heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection. Signal Transduct. Target. Ther. 2021;6:39. doi: 10.1038/s41392-021-00470-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00470-1</ArticleId><ArticleId IdType="pmc">PMC7844799</ArticleId><ArticleId IdType="pubmed">33514685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Tang W., Stancanelli E., Jung E., Syed Z., Pagadala V., Saidi L., Chen C.Z., Gao P., Xu M., et al. Host heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation. Nat. Commun. 2023;14:5777. doi: 10.1038/s41467-023-41453-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41453-w</ArticleId><ArticleId IdType="pmc">PMC10507024</ArticleId><ArticleId IdType="pubmed">37723160</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimond S.E., Mycroft-West C.J., Gandhi N.S., Tree J.A., Le T.T., Spalluto C.M., Humbert M.V., Buttigieg K.R., Coombes N., Elmore M.J., et al. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction. ACS Cent. Sci. 2022;8:527–545. doi: 10.1021/acscentsci.1c01293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c01293</ArticleId><ArticleId IdType="pmc">PMC9136977</ArticleId><ArticleId IdType="pubmed">35647275</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C., Tingting W., Li J.P., Sullivan M.A., Wang C., Wang H., Deng B., Zhang Y. Comprehensive Landscape of Heparin Therapy for COVID-19. Carbohydr. Polym. 2021;254:117232. doi: 10.1016/j.carbpol.2020.117232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2020.117232</ArticleId><ArticleId IdType="pmc">PMC7581413</ArticleId><ArticleId IdType="pubmed">33357843</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher E.C., Lawler P.R., Jensen T.P., Talisa V., Berry L.R., Lorenzi E., McVerry B.J., Chang C.H., Leifer E., Bradbury C., et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. Jama. 2023;329:1066–1077. doi: 10.1001/jama.2023.3651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.3651</ArticleId><ArticleId IdType="pmc">PMC10031504</ArticleId><ArticleId IdType="pubmed">36942550</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuinman P.R., Dixon B., Levi M., Juffermans N.P., Schultz M.J. Nebulized anticoagulants for acute lung injury—A systematic review of preclinical and clinical investigations. Crit. Care. 2012;16:R70. doi: 10.1186/cc11325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11325</ArticleId><ArticleId IdType="pmc">PMC3681399</ArticleId><ArticleId IdType="pubmed">22546487</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Helms J., Totoki T., Levy J.H. Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation. Semin. Thromb. Hemost. 2024 doi: 10.1055/s-0044-1786754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0044-1786754</ArticleId><ArticleId IdType="pubmed">38733977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cools F., Virdone S., Sawhney J., Lopes R.D., Jacobson B., Arcelus J.I., Hobbs F.D.R., Gibbs H., Himmelreich J.C.L., MacCallum P., et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): An open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol. 2022;9:e594–e604. doi: 10.1016/S2352-3026(22)00173-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00173-9</ArticleId><ArticleId IdType="pmc">PMC9243570</ArticleId><ArticleId IdType="pubmed">35779560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodman C., Ali A., Lannon L., Yusuf E., Bansal V., Lal A., Garces J.P.D., Kashyap R. Association of early heparin use among patients with COVID-19 and sepsis and hospital outcomes. Crit. Care Med. 2023;51:110. doi: 10.1097/01.ccm.0000906740.10653.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000906740.10653.05</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Ochoa A.J., Raffetto J.D., Hernandez A.G., Zavala N., Gutierrez O., Vargas A., Loustaunau J. Sulodexide in the treatment of patients with early stages of COVID-19: A randomized controlled trial. Thromb. Haemost. 2021;121:944–954. doi: 10.1055/a-1414-5216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1414-5216</ArticleId><ArticleId IdType="pubmed">33677827</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S., Harenberg J. Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. Thromb. Haemost. 2021;121:849–853. doi: 10.1055/a-1477-3569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1477-3569</ArticleId><ArticleId IdType="pubmed">33831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Cate H. Surviving COVID-19 with Heparin? N. Engl. J. Med. 2021;385:845–846. doi: 10.1056/NEJMe2111151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111151</ArticleId><ArticleId IdType="pmc">PMC8362589</ArticleId><ArticleId IdType="pubmed">34347948</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsharnouby N.M., Eid H.E., Abou Elezz N.F., Aboelatta Y.A. Heparin/N-acetylcysteine: An adjuvant in the management of burn inhalation injury: A study of different doses. J. Crit. Care. 2014;29:e181–e184. doi: 10.1016/j.jcrc.2013.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2013.06.017</ArticleId><ArticleId IdType="pubmed">23932140</ArticleId></ArticleIdList></Reference><Reference><Citation>Stattin K., Lipcsey M., Andersson H., Pontén E., Bülow Anderberg S., Gradin A., Larsson A., Lubenow N., von Seth M., Rubertsson S., et al. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients. J. Crit. Care. 2020;60:249–252. doi: 10.1016/j.jcrc.2020.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2020.08.026</ArticleId><ArticleId IdType="pmc">PMC7470731</ArticleId><ArticleId IdType="pubmed">32920503</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragkou P.C., Palaiodimou L., Stefanou M.I., Katsanos A.H., Lambadiari V., Paraskevis D., Andreadou E., Dimopoulou D., Zompola C., Ferentinos P., et al. Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients. Ther. Adv. Neurol. Disord. 2022;15:17562864221099472. doi: 10.1177/17562864221099472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864221099472</ArticleId><ArticleId IdType="pmc">PMC9136435</ArticleId><ArticleId IdType="pubmed">35646159</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Alés G., Domingo-Relloso A., Quintana-Díaz M., Fernández-Capitán C., Hernán M.A. Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: A target trial emulation. J. Clin. Epidemiol. 2022;151:96–103. doi: 10.1016/j.jclinepi.2022.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2022.08.006</ArticleId><ArticleId IdType="pmc">PMC9385269</ArticleId><ArticleId IdType="pubmed">35987402</ArticleId></ArticleIdList></Reference><Reference><Citation>Shute J.K. Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals. 2023;16:584. doi: 10.3390/ph16040584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040584</ArticleId><ArticleId IdType="pmc">PMC10141002</ArticleId><ArticleId IdType="pubmed">37111341</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon B., Smith R.J., Campbell D.J., Moran J.L., Doig G.S., Rechnitzer T., MacIsaac C.M., Simpson N., van Haren F.M.P., Ghosh A.N., et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9:360–372. doi: 10.1016/S2213-2600(20)30470-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30470-7</ArticleId><ArticleId IdType="pmc">PMC7826120</ArticleId><ArticleId IdType="pubmed">33493448</ArticleId></ArticleIdList></Reference><Reference><Citation>Erelel M., Kaskal M., Akbal-Dagistan O., Issever H., Dagistanli A.S., Balkanci H., Oguz M.S., Qarayeva A., Culha M., Erturk A., et al. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics. 2021;13:1768. doi: 10.3390/pharmaceutics13111768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13111768</ArticleId><ArticleId IdType="pmc">PMC8618458</ArticleId><ArticleId IdType="pubmed">34834183</ArticleId></ArticleIdList></Reference><Reference><Citation>Douen A., Basit A., Panetti R., Farag P., Mbolu G., Popilevsky F., Apergis G. Old medicine for new problems: Potential role of a novel treatment using nebulized heparin in COVID-19 ards. Chest. 2021;160:943A–944A. doi: 10.1016/j.chest.2021.07.879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.07.879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hursitoglu M., Eroz E., Ozgul M.A. Nebulized Heparin for Post-COVID-19-Related Hypoxia. TH Open. 2021;5:e312–e314. doi: 10.1055/s-0041-1732340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1732340</ArticleId><ArticleId IdType="pmc">PMC8324424</ArticleId><ArticleId IdType="pubmed">34377888</ArticleId></ArticleIdList></Reference><Reference><Citation>van Haren F.M.P., van Loon L.M., Steins A., Smoot T.L., Sas C., Staas S., Vilaseca A.B., Barbera R.A., Vidmar G., Beccari H., et al. Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. Br. J. Clin. Pharmacol. 2022;88:2802–2813. doi: 10.1111/bcp.15212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15212</ArticleId><ArticleId IdType="pubmed">34984714</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNucci G., Wilkinson T., Sverdloff C., Babadopulos T., Woodcock A., Shute J., Renato Guazelli P., Gerbase L.F., Mourão P.A.S., Singh D., et al. Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study. Pulm. Pharmacol. Ther. 2023;80:102212. doi: 10.1016/j.pupt.2023.102212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2023.102212</ArticleId><ArticleId IdType="pmc">PMC10064078</ArticleId><ArticleId IdType="pubmed">36990381</ArticleId></ArticleIdList></Reference><Reference><Citation>van Haren F.M.P., Page C., Laffey J.G., Artigas A., Camprubi-Rimblas M., Nunes Q., Smith R., Shute J., Carroll M., Tree J., et al. Nebulised heparin as a treatment for COVID-19: Scientific rationale and a call for randomised evidence. Crit. Care. 2020;24:454. doi: 10.1186/s13054-020-03148-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03148-2</ArticleId><ArticleId IdType="pmc">PMC7374660</ArticleId><ArticleId IdType="pubmed">32698853</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijsers B., Yanginlar C., Maciej-Hulme M.L., de Mast Q., van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020;59:102969. doi: 10.1016/j.ebiom.2020.102969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102969</ArticleId><ArticleId IdType="pmc">PMC7445140</ArticleId><ArticleId IdType="pubmed">32853989</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliynyk O., Barg W., Slifirczyk A., Oliynyk Y., Dubrov S., Gurianov V., Rorat M. Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. Life. 2021;11:1032. doi: 10.3390/life11101032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11101032</ArticleId><ArticleId IdType="pmc">PMC8537389</ArticleId><ArticleId IdType="pubmed">34685403</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Sulaiman K., Aljuhani O., Korayem G.B., Hafiz A., Alalawi M., Badreldin H.A., Altebainawi A.F., Vishwakarma R., Alissa A., Alghamdi A., et al. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: A multicenter propensity-score matched study. Thromb. J. 2022;20:74. doi: 10.1186/s12959-022-00432-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-022-00432-9</ArticleId><ArticleId IdType="pmc">PMC9733230</ArticleId><ArticleId IdType="pubmed">36482388</ArticleId></ArticleIdList></Reference><Reference><Citation>Volteas P., Drakos P., Alkadaa L.N., Cleri N.A., Asencio A.A., Oganov A., Giannopoulos S., Saadon J.R., Mikell C.B., 3rd, Rubano J.A., et al. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. J. Vasc. Surg. Venous Lymphat. Disord. 2022;10:1128–1136. doi: 10.1016/j.jvsv.2022.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2022.04.019</ArticleId><ArticleId IdType="pmc">PMC9212478</ArticleId><ArticleId IdType="pubmed">35716998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Li F., Liu J., Luo Y., Guo H., Yang Q., Xu C., Ma S., Chen H. Intestinal Microbiota—An Unmissable Bridge to Severe Acute Pancreatitis-Associated Acute Lung Injury. Front. Immunol. 2022;13:913178. doi: 10.3389/fimmu.2022.913178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.913178</ArticleId><ArticleId IdType="pmc">PMC9237221</ArticleId><ArticleId IdType="pubmed">35774796</ArticleId></ArticleIdList></Reference><Reference><Citation>Antkowiak R., Bialecki J., Chabowski M., Domoslawski P. Treatment of Microcirculatory Disturbances in Acute Pancreatitis: Where Are We Now? Pancreas. 2022;51:415–421. doi: 10.1097/MPA.0000000000002044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0000000000002044</ArticleId><ArticleId IdType="pubmed">35973016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Tang X., Wu Q., Ren P., Yan Y., Liu W., Pan C. Heparin Protects Severe Acute Pancreatitis by Inhibiting HMGB-1 Active Secretion from Macrophages. Polymers. 2022;14:2470. doi: 10.3390/polym14122470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14122470</ArticleId><ArticleId IdType="pmc">PMC9227308</ArticleId><ArticleId IdType="pubmed">35746047</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil B., Meena L.N., Sharma D.C., Agarwal G., Dadhich Y., Gupta G. Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial. Int. J. Surg. 2022;101:106621. doi: 10.1016/j.ijsu.2022.106621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106621</ArticleId><ArticleId IdType="pubmed">35489648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojaramani K., Sobharani B., Hari Babu Mekala A., Venkat Vineeth A. Study of role of low molecular weight heparin in conjunction with conventional therapy in severe acute pancreatitis. Asian J. Med. Sci. 2022;13:109–116. doi: 10.3126/ajms.v13i9.46834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/ajms.v13i9.46834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X.S., Qiu F., Li J.Q., Fan Q.Q., Zhou R.G., Ai Y.H., Zhang K.C., Li Y.X. Low molecular weight heparin in the treatment of severe acute pancreatitis: A multiple centre prospective clinical study. Asian J. Surg. 2009;32:89–94. doi: 10.1016/s1015-9584(09)60017-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1015-9584(09)60017-8</ArticleId><ArticleId IdType="pubmed">19423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian D., Luan X., Zhang Y. Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop. J. Pharm. Res. 2022;21:1515–1521. doi: 10.4314/tjpr.v21i7.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/tjpr.v21i7.23</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X.-S., Qiu F., Li Y.-X., Li J.-Q., Fan Q.-Q., Zhou R.-G. Effect of Lower-Molecular Weight Heparin in the Prevention of Pancreatic Encephalopathy in the Patient With Severe Acute Pancreatitis. Pancreas. 2010;39:516–519. doi: 10.1097/MPA.0b013e3181c3c954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0b013e3181c3c954</ArticleId><ArticleId IdType="pubmed">20104197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui M., Zhao B., Huang J., Chen E., Qu H., Mao E. Pathogenesis and Therapy of Coagulation Disorders in Severe Acute Pancreatitis. J. Inflamm. Res. 2023;16:57–67. doi: 10.2147/JIR.S388216.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S388216</ArticleId><ArticleId IdType="pmc">PMC9831125</ArticleId><ArticleId IdType="pubmed">36636248</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J.D., Zheng X., Huang Z.Q., Cai S.W., Tan J.W., Li Z.L., Yao Y.M., Jiao H.B., Yin H.N., Zhu Z.M. Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis. Exp. Ther. Med. 2014;8:141–146. doi: 10.3892/etm.2014.1694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1694</ArticleId><ArticleId IdType="pmc">PMC4061186</ArticleId><ArticleId IdType="pubmed">24944612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.F., Qadir P.H., Ahmed S.M., Salih K.M., Abdulla B.A., Mohammed H.R., Salih A.M., Kakamad F.H. Recurrent seasonal severe hypertriglyceridemia-induced acute pancreatitis; a case report. Ann. Med. Surg. 2022;75:103406. doi: 10.1016/j.amsu.2022.103406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103406</ArticleId><ArticleId IdType="pmc">PMC8977940</ArticleId><ArticleId IdType="pubmed">35386772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghizlane E.A., Manal M., Salma T., Abderrahim E.K., Mohammed M., Ikram Z., Fatem-Zahra A., Sanae E.M., Houssam B., Brahim H. Hypertriglyceridemia revealing acute pancreatitis: A case report. Ann. Med. Surg. 2021;70:102914. doi: 10.1016/j.amsu.2021.102914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.102914</ArticleId><ArticleId IdType="pmc">PMC8519797</ArticleId><ArticleId IdType="pubmed">34691438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Anders H.J., Bilyy R., Bowlin G.L., Daniel C., De Lorenzo R., Egeblad M., Henneck T., Hidalgo A., Hoffmann M., et al. Patients with COVID-19: In the dark-NETs of neutrophils. Cell Death Differ. 2021;28:3125–3139. doi: 10.1038/s41418-021-00805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00805-z</ArticleId><ArticleId IdType="pmc">PMC8142290</ArticleId><ArticleId IdType="pubmed">34031543</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy H.M., Al-Gareeb A.I., Al-Hussaniy H.A., Al-Harcan N.A.H., Alexiou A., Batiha G.E. Neutrophil Extracellular Traps (NETs) and COVID-19: A new frontiers for therapeutic modality. Int. Immunopharmacol. 2022;104:108516. doi: 10.1016/j.intimp.2021.108516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108516</ArticleId><ArticleId IdType="pmc">PMC8733219</ArticleId><ArticleId IdType="pubmed">35032828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Chen C., Zhang X., Wang S., Zhu R., Zhou A., Chen S., Feng J. Heparin improves alveolarization and vascular development in hyperoxia-induced bronchopulmonary dysplasia by inhibiting neutrophil extracellular traps. Biochem. Biophys. Res. Commun. 2020;522:33–39. doi: 10.1016/j.bbrc.2019.11.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.11.041</ArticleId><ArticleId IdType="pubmed">31735330</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkumyants A., Buryachkovskaya L., Lomakin N., Antonova O., Docenko J., Ermishkin V., Serebruany V. Effect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19. J. Clin. Med. 2022;11:1995. doi: 10.3390/jcm11071995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11071995</ArticleId><ArticleId IdType="pmc">PMC8999543</ArticleId><ArticleId IdType="pubmed">35407602</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu C., Du Y., Kaltashov I.A. Towards better understanding of the heparin role in NETosis: Feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers. Int. J. Mass. Spectrom. 2021;463:116550. doi: 10.1016/j.ijms.2021.116550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijms.2021.116550</ArticleId><ArticleId IdType="pmc">PMC7939139</ArticleId><ArticleId IdType="pubmed">33692650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelliott P.M., Momota M., Shibahara T., Lee M.S.J., Smith N.I., Ishii K.J., Coban C. Heparin induces neutrophil elastase-dependent vital and lytic NET formation. Int. Immunol. 2020;32:359–368. doi: 10.1093/intimm/dxz084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxz084</ArticleId><ArticleId IdType="pubmed">31879779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Chi L., Zhang Z., Zhao H., Zhang F., Linhardt R.J. Heparin: An old drug for new clinical applications. Carbohydr. Polym. 2022;295:119818. doi: 10.1016/j.carbpol.2022.119818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2022.119818</ArticleId><ArticleId IdType="pubmed">35989029</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh N., Chanda A.H., Rahman M.A., Nainthramveetil M.M., Kumar A., Mathias R.M., Nashwan A.J. Inhalational injury and use of heparin &amp; N-acetylcysteine nebulization: A case report. Respir. Med. Case Rep. 2022;37:101640. doi: 10.1016/j.rmcr.2022.101640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2022.101640</ArticleId><ArticleId IdType="pmc">PMC8956813</ArticleId><ArticleId IdType="pubmed">35345568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushio N., Yamakawa K., Mochizuki K., Hisamune R., Umemura Y., Takasu A. Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: An observational study. Thromb. Res. 2024;241:109095. doi: 10.1016/j.thromres.2024.109095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2024.109095</ArticleId><ArticleId IdType="pubmed">39024902</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz N.R., Hade E.M., Kornblith L.Z., Castellucci L.A., Cushman M., Farkouh M., Gong M.N., Heath A., Hunt B.J., Kim K.S., et al. Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: A prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial. Res. Pract. Thromb. Haemost. 2023;7:102167. doi: 10.1016/j.rpth.2023.102167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2023.102167</ArticleId><ArticleId IdType="pmc">PMC10506136</ArticleId><ArticleId IdType="pubmed">37727846</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., Ibnhadjamor H., Jdidi J., Torjmen S., Kraiem S., Bahloul A., Makni A., Kallel N., Moussa N., Boudaya M., et al. Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study. Front. Cardiovasc. Med. 2022;9:866113. doi: 10.3389/fcvm.2022.866113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.866113</ArticleId><ArticleId IdType="pmc">PMC9133483</ArticleId><ArticleId IdType="pubmed">35647070</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z.Y., Peng M., Fan M.M., Zou Q.F., Li Y.R., Jiang D. Heparin is an effective treatment for preventing liver failure after hepatectomy. World J. Gastroenterol. 2024;30:2881–2892. doi: 10.3748/wjg.v30.i22.2881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v30.i22.2881</ArticleId><ArticleId IdType="pmc">PMC11212721</ArticleId><ArticleId IdType="pubmed">38947296</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>